Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.